FBInvestor
Stocks / Ultragenyx Pharmaceutical In
Institutional Ownership

Ultragenyx Pharmaceutical In

CUSIP 90400D108COMRAREQ1 2026

13D / 13G Filings
45
Schedule 13D/13G on record
Beneficial Filers
13
Distinct reporting persons
Largest Stake
16.9%
Max % of class reported
Institutional Holders
287
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

45 filings · latest Feb 5, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 5, 2026Fmr LLC13G/A3.5%3.35MSEC
2Nov 5, 2025Fmr LLC13G8.3%7.96MSEC
3Apr 24, 2025Blackrock, Inc.13G/A5.1%4.82MSEC
4Feb 12, 2025Sands Capital Management, LLC13G/A4.7%4.30MSEC
5Feb 10, 2025Wellington Management Group LLP13G/A2.7%2.46MSEC
6Nov 14, 2024Rtw Investments, LP13G/A2.1%1.97MSEC
7Feb 14, 2024Rtw Investments, LP13G/A8.4%6.89MSEC
8Feb 14, 2024Price T Rowe Associates Inc /Md/13G/A4.2%3.45MSEC
9Feb 13, 2024Vanguard Group Inc13G/A10.6%8.67MSEC
10Feb 13, 2024Sands Capital Management, LLC13G5.0%4.12MSEC

35 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Ultragenyx Pharmaceutical In.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →